| scholarly article | Q13442814 |
| P2093 | author name string | Lin Zhang | |
| Fabian Benencia | |||
| George Coukos | |||
| Alisha Mohamed-Hadley | |||
| Ronald J Buckanovich | |||
| Richard Carroll | |||
| José R Conejo-García | |||
| Maria C Courrèges | |||
| Nigel Fraser | |||
| P2860 | cites work | Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes | Q24336187 |
| The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions | Q24564834 | ||
| Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells | Q28204913 | ||
| An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow | Q29615498 | ||
| The biology of chemokines and their receptors | Q29619170 | ||
| The nature of the principal type 1 interferon-producing cells in human blood | Q29619763 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant | Q33804845 | ||
| Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer | Q33884613 | ||
| The role of chemokine receptors in primary, effector, and memory immune responses | Q33932742 | ||
| Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins | Q34463480 | ||
| Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence | Q34779144 | ||
| Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm | Q35090817 | ||
| Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells | Q35131235 | ||
| Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. | Q35748149 | ||
| Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model | Q37141874 | ||
| IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver | Q40684546 | ||
| Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses | Q43941683 | ||
| Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines | Q44190727 | ||
| Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation | Q45733161 | ||
| Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. | Q45743053 | ||
| Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus | Q45745964 | ||
| Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity | Q45751042 | ||
| Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. | Q45753117 | ||
| Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 | ||
| Mouse pre-immunocytes as non-proliferating multipotent precursors of macrophages, interferon-producing cells, CD8alpha(+) and CD8alpha(-) dendritic cells | Q77357452 | ||
| Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization | Q77647010 | ||
| HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer | Q79124523 | ||
| Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A | Q80501633 | ||
| P433 | issue | 5 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P1104 | number of pages | 14 | |
| P304 | page(s) | 789-802 | |
| P577 | publication date | 2005-05-31 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer | |
| P478 | volume | 12 |
| Q36146867 | Adhesion to substrates induces dendritic cell endothelization and decreases immunological response. |
| Q47563356 | Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms. |
| Q38933648 | An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites |
| Q38194135 | Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy |
| Q58572502 | CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge |
| Q36429508 | Cooperativity of adaptive and innate immunity: implications for cancer therapy |
| Q35687743 | Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells |
| Q39020907 | Dendritic cells: In vitro culture in two- and three-dimensional collagen systems and expression of collagen receptors in tumors and atherosclerotic microenvironments. |
| Q35559877 | Design and application of oncolytic HSV vectors for glioblastoma therapy |
| Q80674687 | Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene |
| Q30438965 | Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology |
| Q27025330 | Emerging role of Natural killer cells in oncolytic virotherapy |
| Q38912287 | Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment |
| Q26775030 | Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? |
| Q38159802 | Evolution of oncolytic viruses: novel strategies for cancer treatment |
| Q35110920 | First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma |
| Q53272922 | From Benchtop to Bedside: A Review of Oncolytic Virotherapy. |
| Q79239331 | Gene therapy for ovarian cancer |
| Q36138329 | Gene-expression profiling in vaccine therapy and immunotherapy for cancer |
| Q38758325 | Generation and labeling of murine bone marrow-derived dendritic cells with Qdot nanocrystals for tracking studies |
| Q52726371 | High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. |
| Q30355682 | IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. |
| Q39840716 | Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication |
| Q45360866 | Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer |
| Q33895533 | Impact of tumor microenvironment on oncolytic viral therapy |
| Q38657642 | In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. |
| Q39874999 | Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma |
| Q42945799 | Influence of tumors on protective anti-tumor immunity and the effects of irradiation. |
| Q64953266 | Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma. |
| Q47234408 | Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. |
| Q37562080 | Maraba virus as a potent oncolytic vaccine vector |
| Q60924965 | Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues |
| Q34838919 | Modulation of the antitumor immune response by complement |
| Q38119845 | Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments |
| Q45874999 | Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer |
| Q35699072 | ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN. |
| Q55510540 | Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. |
| Q47560690 | Oncolytic Virotherapy and the Tumor Microenvironment |
| Q35625500 | Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. |
| Q38920459 | Oncolytic herpes simplex virus interactions with the host immune system |
| Q35597082 | Oncolytic virotherapy for ovarian cancer |
| Q37818831 | Oncolytic virotherapy of gynecologic malignancies |
| Q38924529 | Oncolytic virus therapy for cancer |
| Q52309503 | Oncolytic viruses as engineering platforms for combination immunotherapy. |
| Q21245758 | Oncolytic viruses as therapeutic cancer vaccines |
| Q37300008 | Oncolytic viruses: a novel form of immunotherapy |
| Q91776793 | Optimizing oncolytic virotherapy in cancer treatment |
| Q59351336 | Please stand by: how oncolytic viruses impact bystander cells |
| Q38795324 | Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses |
| Q39588655 | Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming |
| Q36315580 | Recent progress in the battle between oncolytic viruses and tumours |
| Q37519640 | Reovirus-based therapy for cancer |
| Q37933439 | Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses |
| Q40043393 | Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses |
| Q37681801 | Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression |
| Q42373489 | TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma |
| Q37561072 | The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon |
| Q33924531 | The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells. |
| Q24597894 | Thunder and lightning: immunotherapy and oncolytic viruses collide |
| Q55107050 | Tumor immunotherapy: New aspects of natural killer cells. |
| Q39445325 | Δγ₁134.5 herpes simplex viruses encoding human cytomegalovirus IRS1 or TRS1 induce interferon regulatory factor 3 phosphorylation and an interferon-stimulated gene response |
Search more.